cisatracurium (nimbex) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Cisatracurium is a cis-cis isomer of atracurium and five time as potent as atracurium. The drug is approved by FDA and marketed under the name Nimbex. It is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation due to its antagonistic properties toward nicotinic acetylcholine receptors.   NCATS

Chemistry

  • SMILES: COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC
  • InChIKey: YXSLJKQTIDHPOT-LJCJQEJUSA-N
  • Mol. Mass: 929.16
  • ALogP: 8.07
  • ChEMBL Molecules:
    cisatracurium  
    cisatracurium besylate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$4.0200 - $142.3020
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(1r,1'r,2r,2'r)-atracurium besylate | (1r-cis,1'r-cis)-2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] bisbenzenesulfonate | (1r-cis,1'r-cis)-atracurium besylate | 51w89 | 51 w89 | besilate de cisatracurium | besilato de cisatracurio | cisastracurium | cisastracurium besylate | cisatracurii besilas | cisatracurium | cis-atracurium | cisatracurium besilate | cisatracurium besylate | cisatracurium dibenzenesulfonate | cisatracurium-kation | nimbex | victracurium

Organizations (82)

Research & Development (60)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (35)

Approved Indications (1)


 

Muscle Relaxation (approved 1995)

Experimental Indications - Clinical Trial Phases 1-4 (35)


 

Adrenal Gland Diseases (Phase 4)

Analgesia, Patient-Controlled (Phase 4)

Anesthesia (Phase 4)

Anesthesia, General (Phase 4)

Arthroplasty (Phase 4)

Asthma (Phase 4)

Brain Injuries (Phase 4)

Brain Injuries, Traumatic (Phase 4)

Cognition Disorders (Phase 4)

Conscious Sedation (Phase 4)

Critical Illness (Phase 4)

Delayed Emergence from Anesthesia (Phase 4)

Delirium (Phase 4)

Drugs, Investigational (Phase 4)

Emergence Delirium (Phase 4)

Fasciculation (Phase 3)

Gastrectomy (Phase 4)

General Surgery (Phase 4)

Hemodynamics (Phase 4)

Hysteroscopy (Phase 4)

Intracranial Hypertension (Phase 4)

Intraocular Pressure (Phase 2)

Kidney Failure, Chronic (Phase 2)

Laparoscopy (Phase 4)

Muscle Relaxation (Phase 2/Phase 3)

Neuromuscular Blockade (Phase 4)

Oxidative Stress (Phase 4)

Paralysis (Phase 4)

Perioperative Care (Phase 4)

Postoperative Cognitive Complications (Phase 4)

Postoperative Complications (Phase 4)

Respiratory Distress Syndrome (Phase 4)

Respiratory Insufficiency (Phase 4)

Severe Acute Respiratory Syndrome (Phase 4)

Thoracic Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 54
  • # of Trial Organizations: 60

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue